Global Organoids Market - 2023-2030

Global Organoids Market - 2023-2030

Market Overview

The global organoids market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

Organoids are miniature, self-organized three-dimensional tissue cultures that emanate from stem cells. Such cultures are crafted to replicate much of an organ's complexity or express selected aspects, like producing only certain types of cells.

Market Dynamics

The global organoids market is driven by technological advancements in 3D cell cultures for cancer research, the growing adoption of personalized drugs, increased investment in research and development, and rising demand for biobanking.

Technological advancement in organoids drives the market growth

The rising product launches and technological advancements drive the market in the forecast period. As per the article published in Biochimica et Biophysica Acta in 2022, a significant development in scientific methods has led to the generation of three-dimensional (3D) organoid culture, and 3D printed scaffolds that can recapitulate human biology and diseases more precisely. Organoids have become a regular practice in the everyday lab, owing to their wide use in many biological research applications and the relatively fast pace of technological developments in this field.

In addition, market players are adopting the market strategies such as collaboration and product launches to expand their business. For instance, in January 2020, BioIVT, a leading provider of research models and services for drug and diagnostic development, announced that it had been selected by upcyte technologies GmbH as the exclusive commercial worldwide distributor of its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs). Also, in September 2020, Hubrecht Organoid Technology (HUB) and BGI-Qingdao collaborated to establish a joint Next Generation Diagnostics (NGD) center to improve personalized care, better treatments and cure, as well as faster development of new safe medicines in China. The signing ceremony was conducted online in the Netherlands and China.

The drawbacks of organoids system will hamper the growth of the market

However, an important drawback of organoid systems is their limited time in culture. Epithelial organoids have one-week lifespans, which are usually inadequate to robustly differentiate adult stem cells into the full set of differentiated cell types expected in vivo. This culture time restriction is even more challenging in pluripotent stem cells derived organoids, whose lifespans disagree with the timing of in vivo organogenesis, especially in human systems.

COVID-19 Impact Analysis

The appearance of COVID-19 positively impacted the global organoids market. Although researchers have established organoids' potential relevance for studying new antiviral drugs, their work has yet to lead to marketable treatments. ""Organoid technology has benefited more from the pandemic than the treatment of COVID-19 has benefited from organoids. As per the article published in Nature Methods in 2022, respiratory epithelial cells are derived from the endodermal layer during embryonic development, followed by a complex series of signal transduction occurrences to develop multiple compartments, including proximal and intermediate airways, alveoli, and respiratory bronchioles. SARS-CoV-2 specifically targets epithelial cells in the respiratory system and induces excessive mucus production, cough, and shortness of breath. In severe COVID-19 cases, individuals develop pneumonia, progress to acute respiratory distress syndrome, and finally develop respiratory failure. Therefore, lung airway, alveolar, and bronchial organoids have been commonly involved in monitoring virus infection, exploring pathological changes and identifying potential therapeutics.

Segment Analysis

The intestinal organoids segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The intestinal organoids segment accounts for the largest market share. Three-dimensional Intestinal organoids are in vitro model of the human intestinal epithelium that allows for robust, patient-specific in vitro research of the development and properties of the intestinal epithelium. The majority of Inflammatory Bowel Diseases (IBD) is rapidly increasing across developed and developing countries. IBD, such as Crohn's disease and Ulcerative colitis, affects up to 0.5% of people in the Western world. The recent ability to recapitulate intestinal epithelial dynamics from mini-gut cultures has proven to be a promising step in scientific research and biomedicine.

As per the article published in Scientific Reports in 2020, drug absorption via the intestinal tissue is modulated by membrane permeability and metabolism in intestinal epithelial cells (IECs). In drug discovery research, using human IECs to evaluate membrane permeability and metabolic stability can offer useful information when exploring drug candidate compounds with good bioavailability and trying to predict the fraction absorbed and intestinal availability in humans.

In addition, Merck offers intestinal organoids for cryopreserved patient-derived gastrointestinal organoids or stem cell cultures. Also, the company offers a comprehensive biobank of highly characterized tissue-derived human gastrointestinal organoids from normal and diseased patients.

Geographical Analysis

North America region holds the largest market share of the global organoids market

North America dominates the organoid market and is anticipated to show a similar trend over the forecast period. The market is boosted by factors such as advanced healthcare infrastructure, The increasing prevalence of cancer and gastrointestinal disease, active regional key players, and research and development activities in the region.

The continuously increasing research and development activities in organoids to develop a suitable treatment for a disease such as cancer propel the market in the North American region. For instance, in April 2020, researchers at the University of California San Diego, together with Space Tango, received an award of nearly $5 million from NASA to develop a new dedicated stem cell research laboratory on the International Space Station. The award also supports launching three initial research projects utilizing the stem cell lab, including a project on brain organoids that builds on previous ISS U.S. National Laboratory-sponsored research.

In February 2022, diseases affecting the brain compromise the function of not just nerve cells but also that of their support staff, the glial cells. In a new study, neuroscientists at Houston Methodist have designed neural organoids, also known as “miniature brains,” to contain mature neurons and astrocytic glial cells in relative proportions similar to that in the human brain. Also, in September 2021, A recent collaboration between the Cancer Research UK Manchester Institute and MIT (MA, USA), led by Claus Jorgensen and Linda Griffith, respectively, implemented a new protocol to produce pancreatic organoids. The method relies on a new gel that delivers a more reproducible and accurate model of healthy and cancerous pancreatic tissue.

Competitive Landscape

The organoids market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Thermo Fisher Scientific Inc., Merck KGaA, QIAGEN N.V., GenScript, Promega Corporation, Takara Bio Inc., MERIDIAN BIOSCIENCE Inc., New Engaland Biolabs, Agilent Technologies Inc., and Mirus Bio LLC, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the organoids market globally.

For instance,
• In November 2020, Cellesce Ltd. declared the impending arrival of new patient-derived Breast Cancer organoid lines. These new lines have been fully validated for compatibility with their proprietary organoid development process.

Thermo Fisher Scientific Inc.

Overview:

Thermo Fisher Scientific Inc. is an American company of scientific instrumentation, reagents, consumables, and software services. Headquartered in the United States and founded in 1956. The company offers 3D Cell Cultures – Organoids, Spheroids and Tumoroids.

Product Portfolio

Nunclon Sphera 3D culture system: Nunclon Sphera 3D culture system—built with various formats for spheroid culture (3D tumor spheroids) and organoid culture (brain organoids). The surface of the 3D cell culture supports the formation of 3D spheroids and organoids by encouraging cell-to-cell aggregation through spontaneously produced extracellular matrices (ECM).

The global organoids market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.